Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.68 |
| ▸ | MEN1 | O00255 | 7/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 4/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPY1R | P25929 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3494473 | 0.90 | KMT2A (0.62) | KMT2AMEN1KDM4ELMNAALDH1A1 | |
| SCHEMBL13348144 | 0.89 | KMT2A (0.63) | KMT2AMEN1KDM4ELMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL3492737 | 0.86 | KMT2A (0.67) | KMT2AMEN1KDM4ELMNAALDH1A1 | |
| SCHEMBL3496064 | 0.86 | KMT2A (0.62) | KMT2AMEN1KDM4ELMNAALDH1A1 | |
| SCHEMBL3496729 | 0.83 | KMT2A (0.62) | KMT2AMEN1KDM4ELMNAALDH1A1 | |
| SCHEMBL3496025 | 0.77 | KMT2A (0.52) | KMT2AMEN1KDM4ELMNAALDH1A1 | |
| SCHEMBL3494570 | 0.76 | KMT2A (0.57) | KMT2AMEN1KDM4ELMNAALDH1A1 | |
| SCHEMBL24183527 | 0.74 | SMN1; SMN2 (0.57) | KMT2AMEN1KDM4EPOLBNPC1 | |
| SCHEMBL3494458 | 0.74 | KMT2A (0.52) | KMT2AMEN1KDM4ELMNAALDH1A1 | |
| SCHEMBL3498312 | 0.73 | ACACB (0.60) | KMT2AMEN1KDM4ELMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093777-A1 | SPIRO-RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-2128163-A1 | SPIRO-RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093777-A1 | SPIRO-RING COMPOUND | ACACA, PC, ACACB | KMT2A 2374/4885MEN1 2745/4885KDM4E 1490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.